32 Biosciences, a microbiome-focused company developing diagnostic and therapeutic platforms for gut health, has successfully secured $6 million in funding. This surpasses their initial fundraising target and represents their second successful funding round. The funds will be used to advance key development milestones, including clinical validation of their diagnostic tool, regulatory submissions to the FDA, and preparation for commercial launch. Their diagnostic platform uses AI and mass spectrometry to assess gut microbiome health, providing actionable clinical information.
Their therapeutic innovation is a novel non-antibiotic antimicrobial designed to prevent gut-derived infections by targeting virulence genes and promoting beneficial bacteria. This therapy, proven effective in animal models, aims to significantly reduce infection rates without contributing to antibiotic resistance. The company is targeting late 2026 for FDA clearance of its diagnostic tool and is progressing towards Phase I clinical trials for its therapeutic candidate.
The funding will also support the company's strategic growth, including strengthening its leadership team and advisory boards. 32 Biosciences is committed to revolutionizing healthcare by defining, diagnosing, and restoring the functional health of the gut microbiome to prevent and treat chronic diseases.
The company's success in exceeding its fundraising goals highlights the significant interest in its innovative approach to microbiome medicine and its potential to address unmet medical needs.